TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07030712: A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 67 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT07030712 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07030712 Rescue Dossier →